UNSPSC 51371604: Tramadol hydrochloride

This classification denotes an analgesic agent with the molecular formula C16H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9N7R477WCK, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)-, (+,-)-trans- but more generally known as tramadol hydrochloride, which bears US NIH Compound Identifier 5523. European Medicines Agency schedules Tramadol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04927MIG.

Most nations, for tariff and trade purposes, schedule tramadol hydrochloride under HS 29225000 and SITC 51467. As of Q4 2014, TRAMADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tramadol hydrochloride bears US NLM identifiers UMLS ID C2350089 and NCI Concept Code C29508. SMILES: CN(C)C[C@H]1CCCC[C@@]1(C2CCCC(C2)OC)O.CL.

UNSPSC 51371604 Tramadol hydrochloride is a Commodity code that nominally designates a specific opioid pain medication, but recent state and local procurement activity under this code shows little direct relevance to tramadol itself. Instead, the code appears in opportunities focused on broader pharmaceutical procurement, emergency response supplies, and pharmacy benefit management infrastructure. State and local governments soliciting under this code are sourcing generic multi-source pharmaceuticals, naloxone (an opioid antagonist), drug deactivation systems, and establishing direct-to-manufacturer prescription programs. Issuing bodies include county health departments, state health and human services agencies, and state cooperative purchasing alliances that aggregate demand across multiple jurisdictions and subordinate entities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The code's recent activity emphasizes public health emergency preparedness, cost-management through direct manufacturer relationships, and cooperative purchasing mechanisms that serve multiple jurisdictions simultaneously.